Office of the Nursing & Midwifery Services Director

Seirbhís Sláinte Níos Fearr á Forbairt | Building a Better Health Service

Continuous Professional Education Programme for Registered Nurses and Midwives

to Administer

Tdap Vaccine (Boostrix)

under Medicine Protocol

to children/students in First Year of Second level schools (or equivalent) through a School Immunisation Programme

Medicine Protocol

This Medicine Protocol is a specific written instruction for the administration of **Boostrix** (Tdap):

low dose Tetanus,

Diphtheria,

Pertussis (acellular)

Vaccine to students who may not be individually identified before presentation for vaccination.

Clinical Criteria

- Active immunisation against and prevention of:
  - Diphtheria
  - Tetanus
  - Pertussis (whooping cough)

- ***Booster Immunisation*** to students in first year of second level school (who would have previously completed a primary course when they were younger).

Circumstances in which the Medicine Protocol Applies

- The School Immunisation Programme is delivered annually by the Health Service Executive (HSE).
- The aim of the immunisation programme is to give students in first year of second level school (or equivalent) a booster dose of Tetanus, low dose Diphtheria and Pertussis (acellular) vaccine (reduced antigen content).

Inclusion Criteria for Tdap Boostrix:

- Students in first year in second level school or age equivalent (e.g. home schooled, special schools).
- Students with valid consent.
- For 2020/2021 Boostrix may also be given, to students who are outside the First year cohort group, but are still in school, who missed the Boostrix vaccine in first year due to medical reasons/ exceptional circumstances and whose parents/legal guardians now request Boostrix vaccine.

Exclusion Criteria for Tdap Boostrix:

- Anaphylactic or hypersensitivity reaction to a previous dose of a Tetanus, Diphtheria or Pertussis (either acellular or whole cell) vaccine or any of Boostrix's constituents.

- Students with a contraindication to intramuscular injection (haematological disorder/coagulation disorder e.g. haemophilia, severe thrombocytopenia)

Exclusion Criteria

- Students who are immunocompromised either due to disease or treatment.

- Acute febrile illness: The presence of a minor infection such as a mild upper respiratory infection or low grade fever is not a contraindication to immunisation.

Tdap (Boostrix) Vaccine

Details of the most current and update information of the SmPC and other data is available on the website https://www.hpra.ie

Possible Side Effects

Side effects for adults and adolescents from the age of 10 years onwards:

Very common **(more than 1 per 10 doses of vaccine)**:

- Injection site such as redness, swelling and/or pain (these reactions are less likely when a 25mm needle is used)
- Malaise
- Fatigue
- Headache

Common **(more than 1 in 100 doses and less than 1 in 10)**:

- Dizziness
- Nausea, gastro intestinal disorders
- Pyrexia (fever > 37.5 ˚c)
- Injection site reactions such as injection site mass or abscess

For a full list of side effects refer to https://www.hpra.ie

What are the constituents of Tdap Boostrix Vaccine?

- **Tdap Boostrix** 0.5ml contains:
- Diphtheria toxoid[1]
- Tetanus toxoid[1]
- *Bordetella pertussis antigens*
- Pertussis toxoid[1]
- Filamentous Haemagglutinin[1]
- Pertactin[1]
- [1]Adsorbed on aluminium hydroxide, hydrated aluminium phosphate

Nature and Contents of Pack:

- Tdap Boostrix comes as a single dose of 0.5ml in a pre-filled syringe (Type I glass) with stopper (butyl rubber) with one unattached needle (23G/25mm)

Any Questions?